Candida parapsilosis is a fungal species of yeast that has become a significant cause of sepsis and of wound and tissue infections in immunocompromised people.

Immunocompromised individuals and surgical patients, particularly those undergoing surgery of the gastrointestinal tract, are at high risk for infection with C.

[1] There is currently no consensus on the treatment of invasive candidiasis caused by C. parapsilosis, although the therapeutic approach typically includes the removal of foreign bodies such as implanted prostheses and the administration of systemic antifungal therapy.

[4] C. parapsilosis is considered a killer yeast and fungal antagonist based on its ability to produce chemicals that exert cytotoxic effects on the cells of other organisms.

[1] C. parapsilosis infection of the skin and gastrointestinal tract[1] can occur, in which the production of pseudohyphae is associated with the elicitation of an inflammatory response.

[9] Adhesion capacity is the ability of fungus to adhere to other organisms' cells or tissue, especially mucosal surfaces,[1] which is required for initial colonization.

[11] The risk of C. parapsilosis infection is increased in the setting of implanted medical devices, prostheses, and therapy with hyperalimentation solutions.